NEW YORK – Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday.
If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.
The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...
NEW YORK – At its core, Steve Goldman's lab at the University of Rochester is a stem cell biology lab. Years ago, the neurologist began trying to better understand glial cell biology and how to treat ...
The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...
A panel determined that Tafinlar and Adcetris will be offered to certain patients but passed on several other precision therapies.
After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...
NEW YORK – The US Food and Drug Administration has cleared Umoja Biopharma to begin a Phase I/II trial for its CD22-directed in vivo CAR T-cell therapy, UB-VV400, in patients with relapsed or ...
Primary care docs in Sweden diagnosed Alzheimer's with the same accuracy as dementia specialists when they had access to beta ...
NEW YORK – AstraZeneca has acquired worldwide rights to develop and commercialize Dizal Pharmaceutical's EGFR inhibitor Zegfrovy (sunvozertinib) for up to $1.5 billion, the company announced Tuesday.
The therapy was first granted accelerated approval for solid tumors in 2022 based on the ongoing LIBRETTO-001 trial in adults and another pediatric trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results